MCA Stability Tool

Find stability recommendations for tablets and capsules.

Product Search

Incompatible

Zavedos 5mg capsules (Pfizer Ltd)

Explore other Idarubicin formulations Explore other Idarubicin 5mg capsules suppliers

Stability Notes

Cytotoxic medicine. Not recommended due to handler risk.

Compatible

Zavesca 100mg capsules (Janssen-Cilag Ltd)

Explore other Miglustat formulations Explore other Miglustat 100mg capsules suppliers

Stability Notes

No special precautions for storage.

Provenance

Compatibility information derived from Zavesca 100mg capsules (Janssen-Cilag Ltd).

No Stability Information

Zebinix 200mg tablets (BIAL Pharma UK Ltd)

Explore other Eslicarbazepine formulations Explore other Eslicarbazepine 200mg tablets suppliers

Stability Notes

There are no stability notes available for this medicine.

No Stability Information

Zebinix 200mg tablets (CST Pharma Ltd)

Explore other Eslicarbazepine formulations Explore other Eslicarbazepine 200mg tablets suppliers

Stability Notes

There are no stability notes available for this medicine.

Compatible

Zebinix 800mg tablets (BIAL Pharma UK Ltd)

Explore other Eslicarbazepine formulations Explore other Eslicarbazepine 800mg tablets suppliers

Stability Notes

No special precautions for storage.

Provenance

This compatibility recommendation is derived from Zebinix 800mg tablets (BIAL Pharma UK Ltd).

Compatible

Zebinix 800mg tablets (CST Pharma Ltd)

Explore other Eslicarbazepine formulations Explore other Eslicarbazepine 800mg tablets suppliers

Stability Notes

No special precautions for storage.

Provenance

This compatibility recommendation is derived from Zebinix 800mg tablets (BIAL Pharma UK Ltd).

Compatible

Zebinix 800mg tablets (Pharmaram Ltd)

Explore other Eslicarbazepine formulations Explore other Eslicarbazepine 800mg tablets suppliers

Stability Notes

No special precautions for storage.

Provenance

This compatibility recommendation is derived from Zebinix 800mg tablets (BIAL Pharma UK Ltd).

No Stability Information

Zeffix 100mg tablets (CST Pharma Ltd)

Explore other Lamivudine formulations Explore other Lamivudine 100mg tablets suppliers

Stability Notes

There are no stability notes available for this medicine.

No Stability Information

Zeffix 100mg tablets (GlaxoSmithKline UK Ltd)

Explore other Lamivudine formulations Explore other Lamivudine 100mg tablets suppliers

Stability Notes

There are no stability notes available for this medicine.

No Stability Information

Zeffix 100mg tablets (Sigma Pharmaceuticals Plc)

Explore other Lamivudine formulations Explore other Lamivudine 100mg tablets suppliers

Stability Notes

There are no stability notes available for this medicine.

No Stability Information

Zejula 100mg tablets (GlaxoSmithKline UK Ltd)

Explore other Niraparib formulations Explore other Niraparib 100mg tablets suppliers

Stability Notes

There are no stability notes available for this medicine.

No Stability Information

Zelboraf 240mg tablets (Roche Products Ltd)

Explore other Vemurafenib formulations Explore other Vemurafenib 240mg tablets suppliers

Stability Notes

There are no stability notes available for this medicine.

No Stability Information

Zeldox 40mg capsules (Imported (Sweden))

Explore other Ziprasidone formulations Explore other Ziprasidone 40mg capsules suppliers

Stability Notes

There are no stability notes available for this medicine.

No Stability Information

Zeldox 60mg capsules (Imported (Sweden))

Explore other Ziprasidone formulations Explore other Ziprasidone 60mg capsules suppliers

Stability Notes

There are no stability notes available for this medicine.

No Stability Information

Zeldox 80mg capsules (Imported (Sweden))

Explore other Ziprasidone formulations Explore other Ziprasidone 80mg capsules suppliers

Stability Notes

There are no stability notes available for this medicine.
Print this list

Compatible

Medicines suitable for use in MCAs, although use is likely to be off-label.  Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed).  Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices.  Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.

Use with caution

There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label.  Mitigation measures may need to be considered.  Keep medicines in MCAs for the shortest time necessary.  Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.

Incompatible

Medicines under this category are not suitable for use in MCAs.

No Stability Information

These medicines have not been reviewed by SPS.